Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 argenx
Historique des cours de bourse
Prix actuel de l'action	€864.20
Plus haut sur 52 semaines	€903.00
Plus bas sur 52 semaines	€568.40
Bêta	-0.040
Variation sur 1 mois	7.43%
Variation sur 3 mois	24.49%
Variation sur 1 an	46.47%
Variation sur 3 ans	84.03%
Variation sur 5 ans	201.22%
Évolution depuis l'introduction en bourse	10,839.24%

Nouvelles et mises à jour récentes

Mise à jour du récit • Aug 11

ARGX: Myositis Phase 3 Readouts And Forte Deal Will Drive Future Repricing

The analyst fair value estimate for argenx has increased from €991 to approximately €1,093, with analysts citing a series of higher Street price targets and positive views on Vyvgart performance, the Forte Biosciences acquisition, and the broader immunology pipeline. Analyst Commentary Recent Street commentary on argenx points to strong interest in Vyvgart execution, expanding autoimmune indications and the Forte Biosciences acquisition, with many bullish analysts revisiting their models and price targets through mid 2026.

Mise à jour du récit • Jul 28

ARGX: Myositis Readouts And Forte Deal Will Drive Next Upside

Analysts have nudged their fair value estimate for argenx higher to about €906 from roughly €887, reflecting a slightly lower discount rate and marginally improved long term profitability assumptions, partly supported by a wave of price target increases after the Forte Biosciences acquisition and stronger Vyvgart performance in recent Q2 results. Analyst Commentary Recent research views on argenx cluster around two themes.

Recent updates

Mise à jour du récit • Aug 11

ARGX: Myositis Phase 3 Readouts And Forte Deal Will Drive Future Repricing

Mise à jour du récit • Jul 28

ARGX: Myositis Readouts And Forte Deal Will Drive Next Upside

Mise à jour du récit • Jul 14

ARGX: Myositis Phase 3 Data Will Drive Next Leg Of Upside

The analyst price target for argenx has been raised by approximately €18 to reflect slightly higher modeled fair value and modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions, supported by recent Street research that highlights myositis as a key potential value driver for Vyvgart. Analyst Commentary Recent Street research on argenx continues to cluster around Vyvgart and its potential in myositis, with multiple firms updating valuation models and price targets.

Mise à jour du récit • Jun 30

ARGX: Myositis Phase 3 Readouts Will Shape Future Earnings Power

Analysts have nudged their average price targets for argenx higher, citing a series of recent target increases into the €1,059 to about €1,291 range and arguing that the market may still underappreciate the potential of Vyvgart in autoimmune myositis and related indications. Analyst Commentary Recent research on argenx centers on how Vyvgart and the broader myositis program could influence the company’s long term value, with several firms updating their models ahead of key Phase 3 readouts.

Mise à jour du récit • Jun 16

ARGX: Phase 3 Myositis And ALKIVIA Outcomes Will Test Elevated Stock Expectations

The analyst fair value estimate for argenx has been revised from €614.80 to €644.90 as analysts factor in higher Street price targets and upcoming Phase 3 myositis and ALKIVIA study readouts for Vyvgart and efgartigimod. Analyst Commentary on argenx Recent Street research around argenx highlights a mix of optimism on the clinical pipeline and caution on execution and valuation, giving investors a more balanced picture of risk around Vyvgart and efgartigimod ahead of the Phase 3 myositis and ALKIVIA readouts.

Mise à jour du récit • Jun 02

ARGX: Expanded gMG Label And Myositis Readouts Will Drive Future Repricing Potential

Analysts have nudged their blended price target for argenx higher to about €1,000, reflecting incremental target increases up to €1,291, as they point to upcoming Vyvgart and efgartigimod Phase 3 data and ongoing profitability as key supports for the updated view. Analyst Commentary Bullish analysts are leaning into a constructive view on argenx, pointing to upcoming clinical readouts and recent profitability as key pieces of the story rather than short term trading factors.

Nouveau récit • May 20

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

Investment Memo – argenx SE 1. Executive Summary argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases.

Mise à jour du récit • May 14

ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power

Analysts nudged their blended price target for argenx higher by about €2 to roughly €845, citing a slightly higher fair value estimate, modestly adjusted growth and discount rate assumptions, and support from recent research highlighting Vyvgart momentum and an expanded late stage pipeline. Analyst Commentary Recent research shows a split between analysts trimming targets on fine tuned assumptions and others lifting or reaffirming higher fair value estimates.

Mise à jour du récit • Apr 29

ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential

Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.

Mise à jour du récit • Apr 15

ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power

Analysts have made a modest upward tweak to the fair value estimate for argenx to €842.55, reflecting updated assumptions for Vyvgart momentum, slightly higher revenue growth expectations around 26.7%, a somewhat lower profit margin near 34.7%, and a higher future P/E of about 25.5x following recent price target revisions and ongoing support from research firms despite generally lower headline targets. Analyst Commentary Recent Street research on argenx reflects generally constructive views on Vyvgart execution and the broader pipeline, with some caution around spending plans and the current valuation.

Mise à jour du récit • Apr 01

ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential

Analysts have nudged the blended price target for argenx slightly higher to about €991. This reflects updated assumptions that pair more moderate revenue growth with a higher profit margin outlook and a somewhat richer future P/E, supported by recent research citing steady Vyvgart momentum, consistent profitability and a deep late stage pipeline.

Mise à jour du récit • Mar 17

ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside

Argenx's updated analyst price target reflects a modest recalibration, with fair value edging from about €845 to €839 as analysts factor in ongoing Vyvgart momentum, a slightly lower future P/E assumption and continued profitability. Analyst Commentary Recent Street research on argenx clusters around two themes: execution on Vyvgart and how much of that outlook is already reflected in the share price.

Mise à jour du récit • Mar 03

ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential

The analyst fair value estimate for argenx edges up from €825.51 to €845.07, as analysts trim long term growth and margin assumptions while still pointing to Vyvgart uptake, late stage pipeline breadth, and ongoing price targets mostly above the current level as key supports for the updated price target range. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around argenx, with price targets adjusted both up and down while ratings largely stay positive.

Mise à jour du récit • Feb 17

ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside

Narrative Update Analysts have raised their average price target on argenx by a few euros to €825.51. This reflects updated models that incorporate slightly higher revenue growth assumptions, a modestly higher future P/E multiple and recent target increases from firms citing steady long term confidence in the story.

Mise à jour du récit • Feb 03

ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis

Analysts have lifted their fair value estimate for argenx from US$528.05 to US$614.80, citing updated models that incorporate revised revenue growth, profit margin and future P/E assumptions, in line with a series of recent price target increases from major brokerage firms. Analyst Commentary Recent Street research on argenx has featured a series of higher price targets in both U.S. dollars and euros, reflecting updated models rather than wholesale shifts in underlying views.

Mise à jour du récit • Jan 20

ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing

Analysts have raised their fair value estimate for argenx from about $885 to roughly $990.88, citing higher modeled revenue growth assumptions, updated P/E expectations, and a series of price target increases across the Street. Analysts continue to view the company constructively, even as some lists are being rebalanced.

Mise à jour du récit • Jan 06

ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks

Analysts have lifted their fair value estimate for argenx from $797.32 to $820.09. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E after recent research that highlighted solid Q3 execution, optimism around Vyvgart's opportunity and some recalibration of upside potential.

Mise à jour du récit • Dec 15

ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks

Analysts have nudged their average price target on argenx modestly higher by about $30 per share. This reflects stronger assumed revenue growth and higher future valuation multiples, even as they temper margin expectations in light of a more selective, probability-weighted view of the Vyvgart and empasiprubart pipelines.

Mise à jour du récit • Nov 30

ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations

Argenx's analyst price target has been modestly revised downward by approximately $4 to $766. Analysts are balancing optimism on new clinical data and pipeline expansion with tempered expectations following the recent stock rally.

Mise à jour du récit • Nov 16

ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm

Analysts have raised their price target for argenx by over $20 to approximately $770. They cite strong third-quarter performance, broadening growth drivers across Vyvgart indications, and confidence in the company’s expanding pipeline and commercial prospects.

Mise à jour du récit • Nov 02

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook

Argenx's analyst price target has increased by over $24 to approximately $749. Analysts cite solid quarterly results, pipeline progress, and expanded commercial opportunities as key drivers for the upward revision.

Mise à jour du récit • Sep 25

Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities

argenx’s consensus price target has been revised upward to €724.38 as analysts raise growth forecasts following strong Phase 3 Vyvgart data and expanding market opportunity, while improved revenue projections and robust pipeline momentum continue to offset valuation concerns. Analyst Commentary Bullish analysts are raising price targets on Argenx following positive topline Phase 3 data for Vyvgart in seronegative myasthenia gravis and successful primary endpoint achievement across patient subtypes, which expands the addressable market.

Mise à jour du récit • Aug 29

Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities

argenx’s price target has been raised to €705.90 as analysts cite strong Vyvgart Phase 3 results, raised U.S. sales expectations, visible pipeline catalysts, and resilient uptake despite recent safety concerns. Analyst Commentary Bullish analysts cite Vyvgart’s positive Phase 3 ADAPT SERON results in seronegative generalized myasthenia gravis (gMG), demonstrating clinical improvement and supporting expansion into new patient subtypes.

Mise à jour du récit • Aug 06

Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities

A sharp decline in argenx’s future P/E ratio, despite slightly lower revenue growth forecasts, has contributed to a notable increase in the consensus analyst price target from €665.23 to €700.31. What's in the News Argenx and Unnatural Products Inc.

Nouveau récit • Apr 27

Prefilled Syringe Launch And Pipeline Trials Will Expand Global Reach

Strong pipeline potential from advanced Phase III and proof-of-concept studies could drive new product approvals and market expansion, boosting revenues.

Rendement pour les actionnaires

	ARGX	BE Biotechs	BE Marché
7D	1.1%	2.8%	0.3%
1Y	46.5%	26.8%	18.6%

Rendement vs Industrie: ARGX a dépassé le secteur Belgian Biotechs qui a rapporté 26.8 % au cours de l'année écoulée.

Rendement vs marché: ARGX a dépassé le marché Belgian qui a rapporté 18.6 % au cours de l'année écoulée.

Volatilité des prix

Is ARGX's price volatile compared to industry and market?
ARGX volatility
ARGX Average Weekly Movement	7.0%
Biotechs Industry Average Movement	7.3%
Market Average Movement	3.6%
10% most volatile stocks in BE Market	7.6%
10% least volatile stocks in BE Market	2.0%

Cours de l'action stable: Le cours de l'action de ARGX a été volatil au cours des 3 derniers mois par rapport au marché Belgian.

Volatilité au fil du temps: La volatilité hebdomadaire de ARGX ( 7% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de Belgian.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2008	1,863	Karen Massey	argenx.com

argenx SE, une société biopharmaceutique au stade commercial, développe diverses thérapies pour le traitement des maladies auto-immunes aux États-Unis, au Japon, en Chine, aux Pays-Bas et dans le monde entier. La société propose VYGART et VYGART HYTRULO pour traiter la myasthénie grave généralisée (MGG), la thrombocytopénie immunitaire (ITP) et la polyneuropathie inflammatoire démyélinisante chronique (CIDP). Elle développe également l'efgartigimod pour le traitement de la gMG séronégative et oculaire, des maladies oculaires thyroïdiennes, de l'ITP, de la myosite, de la maladie de Sjögren, de la néphropathie lupique, de la sclérose systémique, du rejet médié par les anticorps et de l'encéphalite auto-immune ; empasiprubart pour la neuropathie motrice multifocale, la PIDC, la fonction retardée du greffon et la dermatomyosite ; et ARGX-119 pour le syndrome myasthénique congénital, la sclérose latérale amyotrophique et l'amyotrophie spinale.

argenx SE Résumé des fondamentaux

Comment les bénéfices et les revenus de argenx se comparent-ils à sa capitalisation boursière ?
ARGX statistiques fondamentales
Capitalisation boursière	€56.41b
Bénéfices(TTM)	€1.47b
Recettes(TTM)	€4.56b

36.8x

Ratio P/E

11.9x

Ratio P/S

Le site ARGX est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ARGX compte de résultat (TTM)
Recettes	US$5.32b
Coût des recettes	US$2.18b
Marge brute	US$3.14b
Autres dépenses	US$1.42b
Les revenus	US$1.72b

Derniers bénéfices déclarés

Jun 30, 2026

Prochaine date de publication des résultats

Oct 22, 2026

Résultat par action (EPS)	27.42
Marge brute	59.07%
Marge bénéficiaire nette	32.27%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de ARGX?

Voir les performances historiques et les comparaisons

Analyse de l'entreprise et données financières

Données	Dernière mise à jour (heure UTC)
Analyse de l'entreprise	2026/08/24 22:24
Cours de l'action en fin de journée	2026/08/24 00:00
Les revenus	2026/06/30
Revenus annuels	2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

Paquet	Données	Cadre temporel	Exemple de source américaine ^*
Finances de l'entreprise	10 ans	Compte de résultat Tableau des flux de trésorerie Bilan	Formulaire 10-K de la SEC Formulaire 10-Q de la SEC
Estimations consensuelles des analystes	+3 ans	Prévisions financières Objectifs de prix des analystes	Rapports de recherche des analystes Blue Matrix
Prix du marché	30 ans	Cours des actions Dividendes, scissions et actions	Données de marché ICE Formulaire S-1 de la SEC
Propriété	10 ans	Actionnaires principaux Délits d'initiés	Formulaire 4 de la SEC Formulaire 13D de la SEC
Gestion	10 ans	L'équipe dirigeante Conseil d'administration	Formulaire 10-K de la SEC Formulaire SEC DEF 14A
Principaux développements	10 ans	Annonces de l'entreprise	Formulaire 8-K de la SEC

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés^.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

argenx SE est couverte par 52 analystes. 28 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

Analyste	Institution
null null	Baird
Colleen Kusy	Baird
Joel Beatty	Baird

argenx (ARGX) Aperçu de l'action

Récompenses

Analyse des risques

Analyst Price Targets

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook

AI Collaboration And Aging Trends Will Expand Autoimmune Biologics Markets

Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins

Top Community Narratives

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

Top Community Narratives

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

Top Analyst Narratives

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook

AI Collaboration And Aging Trends Will Expand Autoimmune Biologics Markets

Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins

argenx SE Concurrents

UCB

BeOne Medicines

Alnylam Pharmaceuticals

PharmaEssentia

Historique des prix et performances

Nouvelles et mises à jour récentes

Investor sentiment improves as stock rises 16%

Zai Lab Limited and Argenx Announces Positive Topline Results From Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis

Vyvgart Achieves Positive Phase 3 Results in Autoimmune Myositis With No Approved Therapies

ARGX: Myositis Phase 3 Readouts And Forte Deal Will Drive Future Repricing

argenx SE (ENXTBR:ARGX) entered into a definitive agreement to acquire Forte Biosciences, Inc. (NasdaqCM:FBRX) for $1.6 billion.

ARGX: Myositis Readouts And Forte Deal Will Drive Next Upside

Recent updates

Investor sentiment improves as stock rises 16%

Zai Lab Limited and Argenx Announces Positive Topline Results From Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis

Vyvgart Achieves Positive Phase 3 Results in Autoimmune Myositis With No Approved Therapies

ARGX: Myositis Phase 3 Readouts And Forte Deal Will Drive Future Repricing

argenx SE (ENXTBR:ARGX) entered into a definitive agreement to acquire Forte Biosciences, Inc. (NasdaqCM:FBRX) for $1.6 billion.

ARGX: Myositis Readouts And Forte Deal Will Drive Next Upside

Argenx to Acquire Forte Biosciences in $2.2 Billion Immunology Pipeline Expansion

Second quarter 2026 earnings: EPS and revenues exceed analyst expectations

argenx SE to Report Fiscal Year 2026 Results on Feb 25, 2027

argenx Collaborates With Chai Discovery for Early Access to AI Antibody Platform

ARGX: Myositis Phase 3 Data Will Drive Next Leg Of Upside

New minor risk - Share price stability

ARGX: Myositis Phase 3 Readouts Will Shape Future Earnings Power

ARGX: Phase 3 Myositis And ALKIVIA Outcomes Will Test Elevated Stock Expectations

Argenx Surges as Vyvgart Gains FDA Approval for All Adult Generalized Myasthenia Gravis Patients

Argenx Unveils Vyvgart Data for Myositis and Sjogren’s at EULAR 2026

Argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’s Disease At EULAR 2026

ARGX: Expanded gMG Label And Myositis Readouts Will Drive Future Repricing Potential

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power

argenx SE Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

First quarter 2026 earnings: EPS exceeds analyst expectations

ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential

argenx SE Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power

ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential

ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside

argenx SE Presents New Data and Pipeline Updates At 2026 AAN Annual Meeting

ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential

Insufficient new directors

Full year 2025 earnings: EPS exceeds analyst expectations

argenx SE, Annual General Meeting, May 06, 2026

Argenx Se Announces Positive Topline Results from Phase 3 Adapt Oculus Trial of Vyvgart in Ocular Myasthenia Gravis

argenx SE to Report Q1, 2026 Results on May 07, 2026

ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside

ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis

ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks

argenx SE Announces Management Changes

argenx SE Announces the Retirement of Peter Verhaeghe from the Board of Directors

argenx SE Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks

Independent Chairman of the Board exercised options and sold €1.5m worth of stock

ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations

Independent Vice Chairman exercised options and sold €3.7m worth of stock

ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm

Independent Vice Chairman exercised options and sold €3.5m worth of stock

Consensus EPS estimates increase by 11%

argenx SE Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook